Figure 2.

To optimize the strategy of pretreatment evaluation, neoadjuvant therapy, surgery, and adjuvant therapy are for early-stage NSCLC. Abbreviations: CT, Computed Tomography; MRI, Magnetic Resonance Imaging; FDG-PET, fluorodeoxyglucose-positron emission tomography; PD-L1, programmed Death-Ligand 1; TMB, tumor mutation burden; HPD, hyperprogressive disease; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer; ICIs, immune checkpoint inhibitors.